BioLineRx Partners with Hemispherian to Develop GLIX1 for Glioblastoma Treatment

BioLineRx Partners with Hemispherian to Advance Innovative Cancer Treatment

BioLineRx Ltd. has entered into a strategic joint venture with Hemispherian AS to advance GLIX1, an innovative oral small molecule aimed at treating glioblastoma (GBM) and other cancers. This collaboration marks a significant step in the fight against GBM, a notoriously aggressive form of brain cancer. GLIX1 operates by enhancing TET2 activity in cancer cells, which leads to double-stranded DNA breaks and triggers apoptosis in tumor cells. Preclinical studies have demonstrated GLIX1's remarkable efficacy against glioblastoma, showing excellent penetration through the blood-brain barrier and a favorable safety profile, positioning it as a promising candidate for further development.

The significance of this collaboration is underscored by the market potential for glioblastoma treatments, which is projected to surpass $3.8 billion annually across the U.S. and EU5 by 2030. With the U.S. Food and Drug Administration (FDA) granting an Investigational New Drug (IND) application for GLIX1 in August 2025, a Phase 1/2a clinical trial is anticipated to commence in the first quarter of 2026. This development aligns with the urgent medical need for effective therapies in GBM, as reflected in the Orphan Drug Designation received from both the FDA and the European Medicines Agency (EMA). Such designations highlight the critical gap in treatment options available for this challenging cancer type.

The partnership not only leverages Hemispherian's expertise in DNA damage response mechanisms but also BioLineRx's regulatory and clinical experience to fast-track GLIX1's availability to patients. The companies are also exploring the drug's potential synergy with PARP inhibitors in homologous recombination proficient cancers, indicating a broader application for GLIX1 beyond GBM. BioLineRx has confirmed that it has adequate financial resources to sustain operations through the first half of 2027, ensuring that the development of GLIX1 remains on track. A conference call is scheduled for September 29, 2025, to provide further insights into this promising collaboration.

In summary, the joint venture between BioLineRx and Hemispherian AS presents a formidable opportunity to address the significant unmet medical need in glioblastoma treatment. By harnessing innovative approaches to target DNA damage response, GLIX1 could become a critical player in the oncology landscape, offering hope to patients battling this aggressive cancer. As the clinical trial approaches, stakeholders in the biotech and healthcare communities eagerly anticipate the potential outcomes of this collaboration.